![]() |
|
|
BD Biosciences, Discovery Labware, Inc., Woburn, Massachusetts
Azamulin [14-O-(5-(2-amino-1,3,4-triazolyl)thioacetyl)-dihydromutilin] is an azole derivative of the pleuromutilin class of antiinfectives. We tested the inhibition potency of azamulin toward 18 cytochromes P450 using human liver microsomes or microsomes from insect cells expressing single isoforms. In a competitive inhibition model, IC50 values for CYP3A (0.030.24 µM) were at least 100-fold lower than all other non-CYP3A enzymes except CYP2J2 (
50-fold lower). The IC50 value with heterologously expressed CYP3A4 was 15-fold and 13-fold less than those of CYP3A5 and CYP3A7, respectively. The reference inhibitor ketoconazole was less selective and exhibited potent inhibition (IC50 values <10 µM) for CYP1A1, CYP1B1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP4F2, and CYP4F12. Inhibition of CYP3A by azamulin appeared sigmoidal and well behaved with the substrates 7-benzyloxy-4-trifluoromethylcoumarin, testosterone, and midazolam. Preincubation of 4.8 µM azamulin in the presence of NADPH for 10 min inhibited
95% of testosterone 6ß-hydroxylase activity compared with preincubation in the absence of NADPH. Catalytic activities of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1 were unaffected by similar experiments. Incubation of azamulin with heterologously expressed CYP3A4 yielded a type I binding spectrum with a spectral dissociation constant of 3.5 µM, whereas no interaction was found with CYP2D6. Azamulin exhibited good chemical stability when stored in acetonitrile for up to 12 days. Aqueous solubility was found to be >300 µM. Azamulin represents an important new chemical tool for use in characterizing the contribution of CYP3A to the metabolism of xenobiotics.
This article has been cited by other articles:
![]() |
J. M. Kovarik, K. Dole, G.-J. Riviere, F. Pommier, S. Maton, Y. Jin, K. C. Lasseter, and R. L. Schmouder Ketoconazole Increases Fingolimod Blood Levels in a Drug Interaction via CYP4F2 Inhibition J. Clin. Pharmacol., February 1, 2009; 49(2): 212 - 218. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Rock, R. S. Foti, and J. T. Pearson The Combination of Chemical and Antibody Inhibitors for Superior P450 3A Inhibition in Reaction Phenotyping Studies Drug Metab. Dispos., December 1, 2008; 36(12): 2410 - 2413. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lu, P. Hatsis, C. Berg, F. W. Lee, and S. K. Balani Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. II. In Vitro-in Vivo Correlation with Ketoconazole Drug Metab. Dispos., July 1, 2008; 36(7): 1255 - 1260. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lu, C. Berg, S. R. Prakash, F. W. Lee, and S. K. Balani Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. III. In Vitro-in Vivo Correlation with Fluconazole Drug Metab. Dispos., July 1, 2008; 36(7): 1261 - 1266. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ghosal, R. Ramanathan, Y. Yuan, N. Hapangama, S. K. Chowdhury, N. S. Kishnani, and K. B. Alton Identification of Human Liver Cytochrome P450 Enzymes Involved in Biotransformation of Vicriviroc, a CCR5 Receptor Antagonist Drug Metab. Dispos., December 1, 2007; 35(12): 2186 - 2195. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Ogden, J. R. Falck, and S. W. Watts The Cytochrome P450 Inhibitor Ketoconazole Potentiates 5-Hydroxytryptamine-Induced Contraction in Rat Aorta J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 606 - 613. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Z. Wang, J. Q. Wu, A. S. Bridges, D. C. Zeldin, S. Kornbluth, R. R. Tidwell, J. E. Hall, and M. F. Paine Human Enteric Microsomal CYP4F Enzymes O-Demethylate the Antiparasitic Prodrug Pafuramidine Drug Metab. Dispos., November 1, 2007; 35(11): 2067 - 2075. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lu, G. T. Miwa, S. R. Prakash, L.-S. Gan, and S. K. Balani A Novel Model for the Prediction of Drug-Drug Interactions in Humans Based on in Vitro Cytochrome P450 Phenotypic Data Drug Metab. Dispos., January 1, 2007; 35(1): 79 - 85. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Mayer, E. K. Dolence, and G. E. Mayer A Real-Time Fluorescence Assay for Measuring N-Dealkylation Drug Metab. Dispos., January 1, 2007; 35(1): 103 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Zhang, L. Wang, G. Chandrasena, L. Ma, M. Zhu, H. Zhang, C. D. Davis, and W. G. Humphreys Involvement of Multiple Cytochrome P450 and UDP-Glucuronosyltransferase Enzymes in the in Vitro Metabolism of Muraglitazar Drug Metab. Dispos., January 1, 2007; 35(1): 139 - 149. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Zhang, S. S. Dehal, T. Ho, J. Johnson, C. Chandler, A. P. Blanchard, R. J. Clark Jr., C. L. Crespi, D. M. Stresser, and J. Wong HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81 Drug Metab. Dispos., May 1, 2006; 34(5): 734 - 737. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-K. Lim, N. Duczak Jr., L. Brougham, M. Elliot, K. Patel, and K. Chan AUTOMATED SCREENING WITH CONFIRMATION OF MECHANISM-BASED INACTIVATION OF CYP3A4, CYP2C9, CYP2C19, CYP2D6, AND CYP1A2 IN POOLED HUMAN LIVER MICROSOMES Drug Metab. Dispos., August 1, 2005; 33(8): 1211 - 1219. [Abstract] [Full Text] [PDF] |
||||